Mission Therapeutics CEO On Clinical Strategy For DUB Drugs

 
• By Lucie Ellis-Taitt

Anker Lundemose, CEO of UK-based Mission Therapeutics, outlines the company's emerging DUBs drug discovery platform on the sidelines of the recent BIO-Europe partnering conference in Berlin.

Video interview

More from Start-Ups & SMEs

More from Business